19 Vestry Street
New York, NY 10013
United States
https://brightmindsbio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Ian McDonald | Co-Founder, CEO, President & Director | N/A | N/A | 1989 |
Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer | 87,61k | N/A | 1978 |
Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director | 177,81k | N/A | 1965 |
Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 239,13k | N/A | 1955 |
Dr. Emer Leahy M.B.A., Ph.D. | Consultant | N/A | N/A | 1967 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
El ISS Governance QualityScore de Bright Minds Biosciences Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.